<DOC>
	<DOCNO>NCT00896493</DOCNO>
	<brief_summary>Non-myeloablative approach allogeneic transplant reasonable option , especially give median age diagnosis 55-60 year frequently present compromised skin patient , increase risk infection . Therefore , propose clinical study allogeneic HSCT use unique non-myeloablative preparative regimen , TLI/ATG , treat advance MF/SS .</brief_summary>
	<brief_title>Ph II Non-myeloablative Allogeneic Transplantation Using TLI &amp; ATG In Patients w/ Cutaneous T Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>3.1 Inclusion Criteria 3.1.1 Stage IIBIV mycosis fungoides Sezary syndrome , fail least 1 standard systemic therapy candidate standard therapy . 3.1.2 Pathology review diagnosis confirm Stanford University Medical Center . 3.1.4 Age &gt; 18 year &lt; = 75 year . 3.1.5 Karnofsky Performance Status &gt; = 70 % . 3.1.6 Corrected DLCO &gt; = 40 % 3.1.7 Left ventricle ejection fraction ( LVEF ) &gt; 30 % . 3.1.8 ALT AST must &lt; = 3X normal . Total bilirubin &lt; = 3 mg/dL unless hemolysis Gilbert 's disease . 3.1.9 Estimated creatinine clearance &gt; = 50 ml/min . 3.1.10 Have relate unrelated HLAidentical donor one antigen/allele mismatch HLAA , B , C DRB1 . 3.1.11 Signed inform consent . 3.3 Donor Inclusion Criteria 3.3.1 Age &gt; =17 . 3.3.2 HIV seronegative . 3.3.3 Signed inform consent . 3.3.4 No contraindication administration GCSF . 3.3.5 Willing central venous catheter place apheresis peripheral vein inadequate . 3.5 Enrollment Enrollment occur eligibility criterion meet . 3.2 Exclusion Criteria 3.2.1 Uncontrolled active infection . 3.2.2 Uncontrolled congestive heart failure angina . 3.2.3 Pregnancy nursing patient exclude study . 3.2.4 Those HIVpositive exclude study due high risk lethal infection hematopoietic cell transplantation . 3.2.5 No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer cancer patient diseasefree five year . 3.4 Donor Exclusion Criteria 3.4.1 Serious medical psychological illness . 3.4.2 Pregnant lactate woman eligible 3.4.3 Prior malignancy within last 5 year except nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>